The tolerability of amphotericin B lipid complex in patients with previous severe infusion reactions to liposomal amphotericin B is unclear. We reviewed the charts of 40 such patients at a tertiary care cancer center and found that amphotericin B lipid complex administration was uneventful in 34 patients (85% [95% confidence interval, 69%-93%]).
predominant lipid formulation of AMB used at our institution), who subsequently received at least 1 dose of ABLC, from January 2006 to April 2012. A severe DDR to LAMB was defined as one necessitating discontinuation of treatment. We reviewed patients' demographic information, underlying diseases, prior reactions to LAMB, premedication for LAMB and subsequent ABLC administration, and types of reactions to ABLC. We classified the drug reactions as doubtful, possible, probable, and definite using the Naranjo scale, a validated clinical tool for determining the likelihood of whether an adverse reaction is actually caused by a drug [5] . We excluded from the analysis 2 patients deemed to have doubtful reactions to LAMB.
The majority (63%) of the 40 patients analyzed were neutropenic (absolute neutrophil count <500/μL) and had hematologic malignancies. The underlying conditions and fungal organisms identified are summarized in Table 1 . The most common documented reactions to LAMB administration were shortness of breath (43%), myalgias (33%), chest pain (20%), and acute fever and/or chills (13%) ( Table 1 ). None of the 5 patients who had fever and/or chills received premedication with acetaminophen, as opposed to 45% (16/35) of those who had different DDRs (P = .07 [Fisher exact test]).
Thirty-four (85% [95% confidence interval, 69%-93%]) patients with previous reactions to LAMB tolerated ABLC without any DDRs. The remaining 6 patients experienced DDRs (3 episodes of chills [2 with acute fever]; 2 episodes of dyspnea, and 1 episode each of chest pain, lower back pain, confusion, tremors, and bradycardia), leading to discontinuation of treatment with ABLC in all 6 patients (Table 2) .
There was no significant difference in the dose between LAMB and ABLC. Infusion rates were significantly longer for ABLC (mean ± SD, 144.45 ± 49.1 mg/hour) than for LAMB (173 ± 49.27 mg/hour, P = .005 [ paired t test]). A trend for higher doses of diphenhydramine prior to ABLC administration was noted. There were no significant differences in infusion rates or premedication between the patients who had a reaction to ABLC and those who did not ( Table 1) .
Three of 5 patients with a history of chills with or without fever related to LAMB infusion had similar reactions to ABLC use. None of these 3 patients received premedication with acetaminophen prior to LAMB or ABLC infusion. Two patients received premedication with diphenhydramine and hydrocortisone, and 1 patient did so with diphenhydramine alone. Only 3 of 35 (9%) patients with reactions to LAMB other than fever or chills had similar reactions to ABLC (P = .017 [Fisher exact test]).
In 45% of the patients, treatment with LAMB was changed to that with ABLC after the first infusion. The shortest period between the 2 formulations for patients who had a reaction to ABLC was 3 days. Two patients who did not have a reaction to ABLC had received systemic steroids within the time period between their LAMB reaction and the initiation of ABLC. In a total of 857 treatment cycles with ABLC, none of the patients had life-threatening reactions requiring hemodynamic support or transfer to the intensive care unit. The median duration of treatment with ABLC was 16 days (range, 2-93 days). Importantly, 2 patients had a history of hypotension and anaphylaxis after receiving LAMB but tolerated ABLC well.
In the present study, we identified all patients with documented severe reactions to treatment with LAMB, who received at least 1 dose of ABLC at a tertiary care cancer center. The majority of them (63%) were high-risk patients with neutropenia and underlying hematologic malignancies. In this patient population, the need for lipid-based formulations of AMB remains, owing to their broad spectra of activity [1, 2, 6] . Our findings indicate that one of the major limitations of LAMB use-occurrence of severe infusion reactions-can be successfully overcome in the majority of cases by using ABLC, maintaining the use of lipid AMB formulations in patients who need broad antifungal coverage.
One important limitation of our study is that it was based on a retrospective review of adverse reactions to LAMB. However, caring for patients with a history of intolerance to a specific medication but limited objective information about the actual reaction is a common scenario in everyday clinical practice. To avoid underestimation of cross-intolerance between ABLC and LAMB, we used a clinical scale to assess the probability that DDRs were actually caused by the medication [5] . We classified all AMB-related adverse events as doubtful, possible, probable, or definite and excluded patients with doubtful reactions; therefore, the majority of the patients included in our study had convincing histories of severe DDRs to LAMB. Because none of these patients had lifethreatening reactions requiring hemodynamic support or transfer to the intensive care unit, our data show that administration of ABLC to patients with a history of severe infusion reactions to LAMB is reasonably safe. Authors have well described that AMB-related infusion reactions are pronounced at the beginning of therapy, but tend to level off after repeated administration [3, 7, 8] . In 45% of our patients, the physicians changed from LAMB to ABLC after the first infusion. Therefore, our data cannot establish whether this change in therapy is truly superior to readministration of LAMB. Nevertheless, most physicians, as well as patients who have experienced severe reactions to a lipid formulation of AMB, would prefer use of a different formulation.
Suggested methods for improving lipid AMB formulation tolerance are slowing the infusion rate and use of premedication [7] [8] [9] . ABLC was infused at a slower rate than was LAMB (Table 1) . Therefore, the better tolerability of ABLC may have partially been a result of slower infusion. Moreover, in a previous report [8] , 93% of the patients who experienced DDRs other than rigors were able to tolerate subsequent LAMB infusion after intravenous diphenhydramine. It is possible that, along with changing AMB lipid formulations and slowing the infusion, clinicians at our institution also tried to optimize premedication, leading to borderline higher doses of diphenhydramine prior to ABLC administration (Table 1) . Nevertheless, there was no difference in infusion rates or premedication between the patients who had reactions to treatment with ABLC and those who did not. Although our study was not sufficiently powered to detect significant differences between patients who had a reaction to ABLC and those who did not, other factors likely contributed to cross-intolerance of the 2 AMB formulations.
In a recent audit of the effect of hydrocortisone-based premedication on ABLC-related DDRs [9] , the overall DDR rate after ABLC infusion with this premedication was 16%, which was significantly lower than the rates in previous reports [3, 7, 8] . The most common DDRs after ABLC were fever and chills [9] , which agreed with our present results ( Table 2 ). In that same study, only patients who had infusion reactions despite undergoing prior administration of hydrocortisone received additional premedication with acetaminophen, prior to subsequent infusions. We observed a significant trend of increased cross-reactivity between ABLC and LAMB in patients with chills, but not in those with other DDRs (Table 2) . However, none of these patients were premedicated with acetaminophen. The number of infusion reactions to ABLC in our study was too small to draw firm conclusions about predictors of cross-reactivity between ABLC and LAMB. Nevertheless, we believe that AMB infusion-related rigors, with or without fever, could have been mitigated by additional premedication with acetaminophen [7] .
In summary, the present study demonstrated that 85% of patients with a history of significant infusion reactions to LAMB tolerated ABLC uneventfully. Although some of the adverse effects may have been attenuated by repeated LAMB infusions, prolonged infusion rates, and maximized premedication, many patients would prefer a different formulation after experiencing a severe DDR to LAMB. Being able to offer ABLC as an alternative lipid AMB formulation with limited cross-intolerance to patients receiving LAMB allows clinicians to continue administering therapy with these formulations.
